{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:56:29Z","timestamp":1782176189951,"version":"3.54.5"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1001\/jamadermatol.2018.1103","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T16:45:26Z","timestamp":1528908326000},"page":"806","source":"Crossref","is-referenced-by-count":47,"title":["Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo"],"prefix":"10.1001","volume":"154","author":[{"given":"Theodore","family":"Rosen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Albareda","sequence":"additional","affiliation":[{"name":"Ferrer Internacional, SA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Medimetriks Pharmaceuticals, Inc, Fairfield, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Garc\u00eda","family":"Alonso","sequence":"additional","affiliation":[{"name":"Ferrer Internacional, SA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Roth","sequence":"additional","affiliation":[{"name":"Medimetriks Pharmaceuticals, Inc, Fairfield, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilonka","family":"Zsolt","sequence":"additional","affiliation":[{"name":"Ferrer Internacional, SA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[{"name":"John P. and Katherine G. McGovern Medical School, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi180019r1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-4362.2003.01647.x","article-title":"Impetigo: an update.","volume":"42","author":"Brown","year":"2003","journal-title":"Int J Dermatol"},{"issue":"7457","key":"doi180019r2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/bmj.329.7457.95","article-title":"Common skin infections in children.","volume":"329","author":"Sladden","year":"2004","journal-title":"BMJ"},{"issue":"8","key":"doi180019r4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10096-011-1179-0","article-title":"Staphylococcus aureus skin and soft tissue infections in primary healthcare in Denmark: a 12-year population-based study.","volume":"30","author":"Dalager-Pedersen","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"doi180019r5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3201\/eid1405.070153","article-title":"Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England.","volume":"14","author":"Hayward","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"doi180019r6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-5945-6-4","article-title":"Increasing incidence of skin disorders in children? a comparison between 1987 and 2001.","volume":"6","author":"Mohammedamin","year":"2006","journal-title":"BMC Dermatol"},{"issue":"2","key":"doi180019r8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/QCO.0b013e3283511d27","article-title":"Streptococcal skin infection and rheumatic heart disease.","volume":"25","author":"Parks","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"doi180019r9","first-page":"42","article-title":"Impetigo: etiology and therapy.","volume":"22","author":"Hirschmann","year":"2002","journal-title":"Curr Clin Top Infect Dis"},{"issue":"4","key":"doi180019r10","first-page":"229","article-title":"Impetigo: diagnosis and treatment.","volume":"90","author":"Hartman-Adams","year":"2014","journal-title":"Am Fam Physician"},{"issue":"2","key":"doi180019r11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"doi180019r12","first-page":"CD003261","article-title":"Interventions for impetigo.","volume":"1","author":"Koning","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"doi180019r13","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1128\/AAC.00079-15","article-title":"High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population.","volume":"59","author":"Antonov","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"doi180019r14","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/jac\/dkv169","article-title":"Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA.","volume":"70","author":"Poovelikunnel","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"doi180019r15","first-page":"223","article-title":"Methicillin-resistant Staphylococcus aureus: a pervasive pathogen highlights the need for new antimicrobial development.","volume":"83","author":"Morell","year":"2010","journal-title":"Yale J Biol Med"},{"issue":"8","key":"doi180019r16","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.2217\/fmb.14.85","article-title":"Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo.","volume":"9","author":"Gropper","year":"2014","journal-title":"Future Microbiol"},{"issue":"3","key":"doi180019r17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.diagmicrobio.2013.11.010","article-title":"Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.","volume":"78","author":"Tato","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"doi180019r18","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1128\/AAC.01509-13","article-title":"In vitro activity of ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.","volume":"57","author":"L\u00f3pez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"doi180019r19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/jac\/49.3.455","article-title":"In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.","volume":"49","author":"Yamakawa","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"20","key":"doi180019r21","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1001\/jama.2013.281316","article-title":"The Declaration of Helsinki, 50 years later.","volume":"310","author":"Ndebele","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"doi180019r22","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archderm.1986.01660230065012","article-title":"Topical antibiotic treatment of impetigo with mupirocin.","volume":"122","author":"Eells","year":"1986","journal-title":"Arch Dermatol"},{"issue":"5","key":"doi180019r23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2165\/00003495-198632050-00002","article-title":"Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.","volume":"32","author":"Ward","year":"1986","journal-title":"Drugs"},{"issue":"7331","key":"doi180019r24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/bmj.324.7331.203","article-title":"Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial.","volume":"324","author":"Koning","year":"2002","journal-title":"BMJ"},{"issue":"5","key":"doi180019r25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/j.1365-2133.2008.08485.x","article-title":"Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial.","volume":"158","author":"Koning","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi180019r26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000107776","article-title":"Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study.","volume":"215","author":"Oranje","year":"2007","journal-title":"Dermatology"},{"issue":"8","key":"doi180019r27","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2217\/fmb.14.82","article-title":"Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.","volume":"9","author":"Gropper","year":"2014","journal-title":"Future Microbiol"},{"issue":"8","key":"doi180019r28","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2217\/fmb.14.83","article-title":"Skin tissue exposure of once- versus twice-daily topical ozenoxacin 2% cream: a Phase I study in healthy volunteers.","volume":"9","author":"Gropper","year":"2014","journal-title":"Future Microbiol"},{"issue":"4","key":"doi180019r29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0732-8893(01)00328-5","article-title":"Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods.","volume":"42","author":"Deshpande","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"doi180019r30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ijantimicag.2003.11.007","article-title":"Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001.","volume":"23","author":"Kresken","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"doi180019r31","doi-asserted-by":"publisher","first-page":"S344","DOI":"10.1086\/589846","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus.","volume":"46","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"9","key":"doi180019r32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1473-3099(02)00369-9","article-title":"Fluoroquinolone resistance among gram-positive cocci.","volume":"2","author":"Hooper","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"doi180019r33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2340\/00015555-0771","article-title":"Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis.","volume":"90","author":"Alsterholm","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi180019r34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ijantimicag.2015.01.009","article-title":"Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus.","volume":"45","author":"Ellington","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"doi180019r35","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/JCM.01984-06","article-title":"Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus.","volume":"45","author":"O\u2019Neill","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"9","key":"doi180019r36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/fmb.14.78","article-title":"Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.","volume":"9","author":"Gropper","year":"2014","journal-title":"Future Microbiol"},{"key":"doi180019r7","first-page":"732","volume-title":"Red Book: 2015 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2015","edition":"30th ed"},{"key":"doi180019r3","unstructured":"Lewis LS. Impetigo. https:\/\/emedicine.medscape.com\/article\/965254 Updated July 13, 2015. Accessed December 3, 2015."},{"key":"doi180019r20","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf. Published June 10, 1996. Accessed April 12, 2018."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2683527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T22:44:56Z","timestamp":1531349096000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.1103"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.1103","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}